The effects of the endogenous pressor agents noradrenaline (NA), and angiotensin II (Ang II), and of the hypotensive agents acetylcholine (ACh) and adenosine (ADS), on blood pressure and heart rate in conscious and unrestrained stroke-prone spontaneously hypertensive rats (SHR-SP) and normotensive Wistar Kyoto rats (WKY) of different ages (4-9 weeks old) were investigated. Pressor responses to NA were enhanced in 7-and 9-week-ol SHR-SP compared with those in WKY, but pressor responses to Ang II in SHR-SP were not different from those in WKY at all ages. The bradycardia following pressor responses to NA and Ang II were markedly attenuated in SHR-SP, especially older ones. Hypotensive responses to ACh were enhanced in SHR-SP, particularly at 9 weeks of age. However, hypotensive responses to ADS were attenuated in SHR-SP, especially at 7 weeks of age. Transient fall of heart rate due to ADS was also attenuated in 7-and 9-week-old SHR-SP. These alterations of hemodynamic or cardiovascular responses in SHR-SP be came more evident in the established stages of hypertension.
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Fig. 1. Typical recordings of the effects of intravenous injection of noradrenaline (NA) and angiotensin II (Ang II) on blood pressure (BP) and heart rate (HR) in conscious and unrestrained 7-week-old SHR-SPWKY . Almost no bradycardic responses in SHR-SP were observed on administration of NA and Ang II. The pressor effects of NA in SHR-SP at 7 and 9W of age were greater than those in age-matched WKY, and also greater than those in SHR-SP at 4 and 5 W of age (Fig. 2) . Almost no changes in the pressor effects of NA in WKY were observed with aging except at 9W, when the smallest dose of NA caused a significantly greater response than at 4W. The bradycardias following pressor responses with NA were markedly attenuated in SHR-SP, especially at advanced ages ( Fig. 1, 2) .
Ang II (10-100ng/kg, i.v.) also caused dose-dependent increases of MAP and decreases of HR. The pressor effects of Ang II in SHR-SP were similar to those in age-matched WKY except at 4W, when a more potent pressor effect was observed in SHR-SP at 30ng/kg, i.v. (Fig. 3) . The pressor effects of Ang II in both strains did not change with aging. However, the bradycardia following pressor responses with Ang II was attenuated in SHR-SP at 5, 7 and 9W, and this attenuation progressed with aging (Fig. 3) . Effects of hypotensive agents: Typical recordings of the effects of ACh and ADS on MAP and HR are shown in Figure 4 . Intravenous injection of ACh (0.1-1g/kg) caused dose-dependent decreases in MAP and increases in HR. Decreases in HR with ACh were not observed at any age in SHR-SP and WKY. Absolute hypotensive responses to ACh in SHR-SP were greater than those in WKY at all ages and increased with aging (Fig. 5) . The percent decreases in MAP with ACh were also greater in SHR-SP than those in WKY at 4, 7 and 9W (Fig. 6) . The percent decreases in MAP with ACh did not change with aging in WKY, but were greater in 9W than in 4 and 5W SHR-SP. Increases in HR following hypotensive response in SHR-SP were similar to those of age-matched WKY at all ages (data not shown).
Intravenous injection of ADS (30-300ng/kg) caused dose-dependent decreases in MAP and transient decreases followed by increases in HR. Absolute hypotensive responses to ADS in SHR-SP did not differ from those in WKY at Jpn. Heart J. July, 1993 sponses to NA were also reported to have been enhanced8). However, other investigators showed that the pressor responses to both NA and Ang II in SHR were not different from those in WKY in the intact conscious state.9) For the vascular reactivities in SHR-SP, several investigators showed enhanced vasoconstriction following both NA and Ang II2-4). Thus, our result, which shows specifi enhancement of the pressor effect of NA, can not be fully explained by the previously reported vascular reactivities in SHR-SP. Our results may suggest that the vascular reactivity to NA but not to Ang II in the resistance vessels, which really determines systemic blood pressure, is enhanced, and it might be related to the enhancement of -adrenergic responses or reduction of -adrenergic responses.15) Bradycardias induced by both NA and Ang II were attenuated in SHR-SP, especially in older ones. Attenuation of the baroreceptor reflex has been widely reported in several hypertensive model animals and hypertensive patients.16-2 Furthermore, this attenuation has been suggested to be secondary to hypertension.18),19) Our results on the attenuation of reflex bradycardia in SHR-SP seemed to correlate with these previous findings, because the attenuation of reflex bradycardia in SHR-SP became clearer with aging. It is noteworthy that the reflex bradycardia following NA administration in SHR-SP was attenuated even in 4W animals when no significant difference in MAP between SHR-SP and WKY was observed. Further studies are needed to elucidate the reflex responses in SHR-SP at the very young stage.
Percent decreases in MAP by ACh were greater in SHR-SP than in WKY at 4, 7 and 9W. The enhancement of this effect in SHR-SP was most obvious at 9W. These results suggest that hypotensive responses with ACh in SHR-SP were enhanced compared with those in WKY, especially in older animals. However, it was recently reported that the percent decreases in MAP following ACh were attenuated in SHR.12) In the present experiments, the vasodilating effect of ACh might have been responsible for the hypotensive responses because no negative chronotropic effect was observed. Several investigators showed that the endothelium-dependent vasorelaxation with ACh against serotonin or noradrenaline contraction was diminished in SHR-SP.5)-7) However, vasorelaxation with ACh against endothelin contraction in SHR-SP was reported to have been enhanced compared with those in WKY.22) Our experiments may suggest that the vasodilation of physiologically regulated resistance vessels following ACh is enhanced in SHR-SP.
Intravenous injection of ADS caused transient decreases in HR followed by increases in SHR-SP and WKY. Thus, the hypotensive effect of ADS might be caused by both its vasodilating effect and a transient decrease in HR. The percent decreases in MAP caused by ADS were attenuated in SHR-SP compared Jpn. Heart J. July, 1993 with WKY at almost all ages. Transient decrease in HR in SHR-SP was attenuated at 7 and 9W. This attenuation may contribute to the attenuation of the hypotensive effect of ADS in SHR-SP. ADS causes bradycardia via the cardiac A1-K+ type receptor and causes vasorelaxation via the vascular A2 receptor.23 Recently, it was reported that vascular relaxation caused by ADS is also mediated by ATP-sensitive potassium channels.24),25) Our findings may suggest that the activity of cardiac or vascular receptors for ADS is reduced in SHR-SP. In conscious SHR, intravenous infusion of ADS caused a greater fall in blood pressure and heart rate than in WKY.13) Although the reason for this discrepancy is not clear, further studies of the relationship between the reactivity to ADS and hypertension are needed.
In summarizing our present data concerning pressor and hypotensive agents, the pressor effect of NA but not Ang II was enhanced and reflex bradycardia was diminished in SHR-SP. The hypotensive effect of ACh was enhanced, but that of ADS was attenuated in SHR-SP. Augmented or attenuated hypotensive responses to ACh or ADS in SHR-SP were contrary to the data reported in SHR. These discrepancies between SHR-SP and SHR still remain to be elucidated.
In conclusion, 1) the pressor effect of NA was enhanced, 2) bradycardias following pressor effects with NA or Ang II were attenuated, and 3) hypotensive and bradycardic responses of ADS were attenuated in the developing stages of hypertension in SHR-SP. Mechanisms underlying these phenomena might contribute to the development or maintenance of hypertension in SHR-SP.
